Comparison between efficacy of CO2 laser alone versus combination of cryotherapy and intralesional meglumine antimoniate in the treatment of cutaneous Leishmaniasis

Alam Zaib, Qamar ud Din Khan, Asher Ahmad Mashhood, Uzma Naeem

Abstract


Objective To determine the efficacy of CO2 laser therapy in comparison to combined cryotherapy and intralesional meglumine antimoniate therapy in the treatment of cutaneous Leishmaniasis.

 

Study Design Randomized controlled trial.

 

Place and duration of Study Department of dermatology CMH Peshawar from April 2016 to April 2017.

 

Methodology 136 patients between ages of 15 to 60 years with clinically diagnosed cutaneous Leishmaniasis, positive LT bodies in a skin smear or histopathology were included in the study. Patients with symptoms of 1-3 months’ duration were enrolled and two groups were formed. One treated with CO2 laser and retreated after 04 weeks if required. The second group was treated both with cryotherapy and intralesional meglumine antimoniate injection biweekly for 8 weeks. Clinical assessment for cure was done at 8th week for both groups. Chi-square test was used to compare the efficacy in both the groups.

 

Results Mean age in group A was 28.5±4.9 years while in group B it was 29.5±4.8 years. The overall efficacy after 08 weeks in group A patients who had clinical cure was 79.4 % while it was 73.5% in group B.

 

Conclusion CO2 laser therapy in the treatment of cutaneous Leishmaniasis was found reliable and cost effective in comparison to combined cryotherapy and intralesional meglumine antimoniate therapy with benefit of less procedure work on patients.

 


Keywords


CO2 fractional laser, cutaneous Leishmaniasis, cryotherapy, intralesional meglumine antimoniate

Full Text:

PDF

References


Alvar J, Vélez ID, Bern C, Herrero M, Desjeux P, Cano J, et al. Leishmaniasis Worldwide and Global Estimates of Its Incidence. PLoS ONE. 2012; 7(5): e35671 doi.

Afghan AK, Kassi M, Kasi PM, Ayub A, Kakar N, Marri SM. Clinical manifestations and distribution of cutaneous leishmaniasis in Pakistan. J Trop. 2011; 2011: 359145.

Dilnawaz M, Hussain K, Malik NJ, Khan LM, Mazhar H, Soomro AA. Clinical audit on treatment of mucosal and multiple cutaneous leishmaniasis lesions with pentavalent systemic antimony. JPAD 2015; 25 (1): 40-43.

Esfandiarpour I, Farajzadeh S, Rahnama Z, Fathabadi EA, Heshmatkhah A. Adverse effects of intralesional meglumine antimoniate and its influence on clinical laboratory parameters in the treatment of cutaneous leishmaniasis. Int J Dermatol 2012; 51(10): 1221-5.

Oliveira AL, Brustoloni YM, Fernandes TD, Dorval ME, Cunha RV, Bóia MN. Severe adverse reactions to meglumine antimoniate in the treatment of visceral leishmaniasis: a report of 13 cases in the south western region of Brazil. Trop Doct 2009 Jul; 39(3): 180-2.

Shamsi S, Zandi S, Aghaie H, Heshmatkhah A. Efficacy of CO2 laser for treatment of anthroponotic cutaneous leishmaniasis, compared with combination of cryotherapy and intralesional meglumine antimoniate. J Eur Acad Dermatol Venereol 2011 May; 25(5): 587-91.

Berman JD, Neva FA. Effect of temperature on multiplication of Leishmania amastigotes within human monocyte-derived macrophages in vitro. Am J Trop Med Hyg 1981; 30(2): 318–321.

Esfandiarpour I, Mohebbi A, Dabiri S, Farajzadeh S, Rahnama Z, Mohammadi S, et al. The efficacy of carbon dioxide laser in the treatment of chronic and lupoid cutaneous leishmaniasis in Kerman City: A randomized clinical trial. J Kerman Univ Med Sci 2014; 21(4): 267–76.

Asilian A, Sharif A, Faghihi G, Enshaeieh S, Shariati F, Siadat A. Evaluation of CO2 laser efficacy in the treatment of cutaneous Leishmaniasis. Int J Dermatol 2004; 43(10): 736-8.


Refbacks

  • There are currently no refbacks.


ISSN: 1560-9014